Medscape5d
Use of Controller Medications in Patients Initiated on a Long-Acting Beta2-Adrenergic Agonist Before and After Safety Alerts
The previous use of a controller medication was lower than expected in patients who were started on an LABA within this managed care population. The overall frequency of the prescribing of ...
Medscape21d
Safety and Efficacy of Combined Long-Acting Beta-Agonists and Inhaled Corticosteroids vs Long-Acting Beta-Agonists Monotherapy for Stable COPD
Background: Current guidelines recommend the use of inhaled corticosteroids (ICSs) added to long-acting β 2-agonists (LABAs ... of LABAs/ICSs compared with LABA monotherapy for patients with ...
Nature19d
A brief history of inhaled asthma therapy over the last fifty years
Over the last 10 years, the long-acting beta-agonists (LABAs) have become an important add-on therapy for the management of asthma, and they are now often used with ICS in a single ICS/LABA ...
Monthly Prescribing Reference3y
Advair Diskus 100/50
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...
pharmaphorum2d
Novartis on point in EU for asthma triple as CHMP backs Enerzair
Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...
Monthly Prescribing Reference12y
Advair Diskus 500/50
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...
hospitalhealthcare4d
Chronic asthma guideline key updates and implications: pharmacological management
Part two of this series sees Ravijyot Saggu explore pharmacological management recommendations from the new joint chronic ...
pharmaphorum7y
Chiesi backs up COPD triple therapy with real world study
Trimbow (beclometasone+formoterol+glycopyrronium) combines an inhaled corticosteroid (ICS), a long-acting beta adrenoceptor agonist (LABA) and a long-acting muscarinic antagonist (LAMA ...